FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

H F P Hillen

Research Profile

Disorders

Anatomy

Geographic Areas

Netherlands

Procedures

Concepts & Ideas

Chemicals & Drugs

Physiology

Cell Divisions

Co-author Network

Publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of H F P Hillen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: H F P Hillen
[Beyond happiness].
Nederlands tijdschrift voor geneeskunde 2012;156(51):A5749.
2010: H F P Hillen
[First professor of medicine in Maastricht: Pelerin].
Nederlands tijdschrift voor geneeskunde 2010;154():A1525.
2010: H F P Hillen
[Thomas Schwencke and Wolfgang Amadeus Mozart].
Nederlands tijdschrift voor geneeskunde 2010;154():A2195.
2008: Ernst J M Speel; Agnes J van de Wouw; S M H Claessen; Annick Haesevoets; Anton H N Hopman; Anneke A M van der Wurff; Rainhardt Osieka; Reinhard Buettner; H F P Hillen; Frans C S Ramaekers
Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
International journal of cancer. Journal international du cancer 2008;123(6):1292-300.
2006: Marten Nijziel; René Van Oerle; H F P Hillen; Karly Hamulyák
From Trousseau to angiogenesis: the link between the haemostatic system and cancer.
The Netherlands journal of medicine 2006;64(11):403-10.
2006: Coen I M Baeten; Karolien Castermans; Guido Lammering; Femke Hillen; Bradly G Wouters; H F P Hillen; Arjan W Griffioen; Cornelius G M I Baeten
Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer.
International journal of radiation oncology, biology, physics 2006;66(4):1219-27.
2006: Coen I M Baeten; Karolien Castermans; H F P Hillen; Arjan W Griffioen
Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006;4(11):1351-7.
2004: Jessica C A Bouma-Ter Steege; Coen I M Baeten; Victor L J L Thijssen; Sietske Satijn; Inge C L Verhoeven; H F P Hillen; John Wagstaff; Arjan W Griffioen
Angiogenic profile of breast carcinoma determines leukocyte infiltration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7171-8.
2004: Agnès J van de Wouw; R L H Jansen; Arjan W Griffioen; H F P Hillen
Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT.
Anticancer research 2004;24(1):297-301.
2003: Marten Nijziel; René Van Oerle; D Hellenbrand; Elisabeth C M van Pampus; H F P Hillen; Karly Hamulyák
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Journal of thrombosis and haemostasis : JTH 2003;1(5):982-6.
2003: Agnès J van de Wouw; R L H Jansen; Ernst J M Speel; H F P Hillen
The unknown biology of the unknown primary tumour: a literature review.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):191-6.
2002: Coen I M Baeten; John Wagstaff; I C L Verhoeven; H F P Hillen; Arjan W Griffioen
Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment.
British journal of cancer 2002;87(3):344-7.
2002: Agnès J van de Wouw; M L G Janssen-Heijnen; Dorry Boll; H F P Hillen
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.
European journal of cancer (Oxford, England : 1990) 2002;38(3):409-13.
2001: H F P Hillen
Education and training in internal medicine in Europe.
Postgraduate medical journal 2001;77(913):727-31.
2001: Arjan W Griffioen; Daisy W J van der Schaft; AF Barendsz-Janson; A Cox; Harry A J Struijker Boudier; H F P Hillen; Kevin H Mayo
Anginex, a designed peptide that inhibits angiogenesis.
The Biochemical journal 2001;354(Pt 2):233-42.
2001: R de Boer; H F P Hillen; R M H Roumen; harm rutten; M J C van der Sangen; Adri C Voogd
Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer.
The British journal of surgery 2001;88(1):118-22.
2000: H F P Hillen
Unknown primary tumours.
Postgraduate medical journal 2000;76(901):690-3.
2000: Janneke M de Rijke; Leo J Schouten; H F P Hillen; L A Kiemeney; J W Coebergh; PA van den Brandt
Cancer in the very elderly Dutch population.
Cancer 2000;89(5):1121-33.
2000: Marten Nijziel; René Van Oerle; Elisabeth C M van Pampus; H C de Vet; H F P Hillen; Karly Hamulyák
Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients.
American journal of hematology 2000;64(4):282-6.
2000: H F P Hillen; Pierre Hupperets
[Breast cancer in patients, 70 years or older].
Nederlands tijdschrift voor geneeskunde 2000;144(23):1099-104.
2000: RI Lalisang; E E Voest; Jacques A Wils; J W Nortier; F L G Erdkamp; H F P Hillen; Jacob Wals; Harry C Schouten; Geert H Blijham
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
British journal of cancer 2000;82(12):1914-9.
2000: Selma C Tromp; mirjam oude egbrink; Ruud Dings; S van Velzen; Dick W Slaaf; H F P Hillen; Geert Jan Tangelder; Robert S Reneman; Arjan W Griffioen
Tumor angiogenesis factors reduce leukocyte adhesion in vivo.
International immunology 2000;12(5):671-6.
1999: N P Pappas; H F P Hillen; John Wagstaff; Arjan W Griffioen
[Angiogenesis and the regulation of antitumor defense].
Nederlands tijdschrift voor geneeskunde 1999;143(30):1555-9.
1999: H F P Hillen
Gastroenterology and internal medicine in Europe: united we stand.
Italian journal of gastroenterology and hepatology 1999;31(5):353-6.
1998: Arjan W Griffioen; Selma C Tromp; H F P Hillen
Angiogenesis modulates the tumour immune response.
International journal of experimental pathology 1998;79(6):363-8.
1998: R L H Jansen; Susan R Joosten-Achjanie; A Volovics; Jan-Willem Arends; Pierre Hupperets; H F P Hillen; Harry C Schouten
Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer.
Anticancer research 1998;18(6A):4455-62.
1998: Arjan W Griffioen; AF Barendsz-Janson; Kevin H Mayo; H F P Hillen
Angiogenesis, a target for tumor therapy.
The Journal of laboratory and clinical medicine 1998;132(5):363-8.
1998: R L H Jansen; Pierre Hupperets; Jan-Willem Arends; Susan R Joosten-Achjanie; A Volovics; Harry C Schouten; H F P Hillen
MIB-1 labelling index is an independent prognostic marker in primary breast cancer.
British journal of cancer 1998;78(4):460-5.
1998: H C Lichtenbeld; AF Barendsz-Janson; H van Essen; Harry A J Struijker Boudier; Arjan W Griffioen; H F P Hillen
Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model.
International journal of cancer. Journal international du cancer 1998;77(3):455-9.
1998: AF Barendsz-Janson; Arjan W Griffioen; A D Muller; M C van Dam-Mieras; H F P Hillen
In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis.
Journal of vascular research 1998;35(2):109-14.
1998: R L H Jansen; Pierre Hupperets; Jan-Willem Arends; Susan R Joosten-Achjanie; A Volovics; H F P Hillen; Harry C Schouten
pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer.
Anticancer research 1998;18(1B):577-82.
1998: R H Jansen; Susan R Joosten-Achjanie; Jan-Willem Arends; A Volovics; Pierre Hupperets; Harry C Schouten; H F P Hillen
CD44v6 is not a prognostic factor in primary breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):109-11.
1998: AF Barendsz-Janson; A D Muller; H H Lichtenbeld; M C Van Dam-Mieras; H F P Hillen
Cellular arrangement of human breast cancer cell lines determines hemostatic parameters.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(2):104-12.
1997: Pierre Hupperets; L Volovics; Leo J Schouten; Jos J Jager; Harry C Schouten; H F P Hillen; Geert H Blijham
The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer.
American journal of clinical oncology 1997;20(6):546-51.
1997: R L H Jansen; H F P Hillen; Harry C Schouten
Prognostic and predictive factors in breast cancer.
The Netherlands journal of medicine 1997;51(2):65-77.
1997: H F P Hillen; L E Hak; Susan R Joosten-Achjanie; Jan-Willem Arends
Microvessel density in unknown primary tumors.
International journal of cancer. Journal international du cancer 1997;74(1):81-5.
1996: H H Lichtenbeld; Maria C E van Dam-Mieras; H F P Hillen
Tumour angiogenesis: pathophysiology and clinical significance.
The Netherlands journal of medicine 1996;49(1):42-51.
1995: H F P Hillen
[Metastases from unknown primary tumor].
Nederlands tijdschrift voor geneeskunde 1995;139(44):2225-8.
1994: P Dubbeld; H F P Hillen; H C Schouten
Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP)
European journal of haematology 1994;52(4):233-5.
1991: P Dubbeld; C van der Heul; H F P Hillen
Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP).
The Netherlands journal of medicine 1991;39(1-2):6-10.